Bio-Techne Corporation

03/04/2026 | Press release | Distributed by Public on 03/04/2026 17:48

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Crouse Steven C.
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President - Diag & Spatial Bi
(Last) (First) (Middle)
614 MCKINLEY PLACE NE
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
(Street)
MINNEAPOLIS, MN 55413
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5,894 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) (2) (2) Common Stock 1,588 1,588 D
Restricted Stock Units (1) (3) (3) Common Stock 1,800 1,800 D
Restricted Stock Units (1) (4) (4) Common Stock 1,379 1,379 D
Restricted Stock Units (1) (5) (5) Common Stock 3,737 3,737 D
Restricted Stock Units (1) (6) (6) Common Stock 6,529 6,529 D
Stock Option (right to buy) $97.13 (7) 04/01/2028 Common Stock 3,856 3,856 D
Stock Option (right to buy) $120.46 (7) 08/06/2028 Common Stock 19,032 19,032 D
Stock Option (right to buy) $94.52 (8) 08/15/2029 Common Stock 24,560 24,560 D
Stock Option (right to buy) $84.61 (9) 08/15/2030 Common Stock 12,649 12,649 D
Stock Option (right to buy) $73.46 (10) 05/01/2031 Common Stock 7,327 7,327 D
Stock Option (right to buy) $74.91 (11) 08/15/2034 Common Stock 17,133 17,133 D
Stock Option (right to buy) $48.61 (12) 06/02/2035 Common Stock 5,434 5,434 D
Stock Option (right to buy) $53.6 (13) 08/15/2035 Common Stock 19,151 19,151 D
Performance Restricted Stock Units (1) 03/02/2026 A 2,387 (14) (14) Common Stock 2,387 $ 0 2,387 D
Restricted Stock Units (1) 03/02/2026 A 735 (15) (15) Common Stock 735 $ 0 735 D
Stock Option (right to buy) $57.82 03/02/2026 A 1,911 (16) 03/02/2036 Common Stock 1,911 $ 0 1,911 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Crouse Steven C.
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413
President - Diag & Spatial Bi

Signatures

/s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney previously filed. 03/04/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(2) 794 restricted stock units vest on 5/1/2026 and 5/1/2027.
(3) 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
(4) 1,379 restricted stock units vest on 8/15/2026.
(5) 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
(6) 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
(7) 100% vested.
(8) Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
(9) Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
(10) Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
(11) Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
(12) Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
(13) Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
(14) Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(15) 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.
(16) Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Bio-Techne Corporation published this content on March 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 04, 2026 at 23:49 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]